- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00396409
Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis
A Randomized, 20 Week, Double-blind, Placebo-controlled, Parallel-group, Multiple-dose, Multicenter Study to Assess the Efficacy and Safety of Omalizumab in Combination With Depigoid, Versus Depigoid Only, in Adult and Adolescent Patients With Seasonal Allergic Asthma and Comorbid Seasonal Allergic Rhinoconjunctivitis - Open-label Depigoid Monotherapy Extension Periods 2007 and 2008-
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was an open-label extension period of the previously randomized, multicenter, double-blind, placebo-controlled, parallel-group trial to demonstrate the benefit of pre- and co-seasonal combination therapy with anti-IgE (omalizumab) and specific immunotherapy (Depigoid) in patients with seasonal allergic asthma and co-morbid seasonal allergic rhinoconjunctivitis. During the open-label period, all patients received Depigoid monotherapy for two follow-up seasons every 4 weeks, 26 injections in total. The extension period was performed to evaluate the influence of omalizumab on the follow-up treatment with Depigoid in seasonal asthma.
This study was a follow-up to the core IGE025ADE03 study, in which patients received omalizumab treatment. In this follow-up study, no patient received omalizumab.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Nuremberg, Germany
- Novartis Investigator Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females of any race who are 12-45 years of age with a body weight ≥ 20 kg and ≤ 150 kg and with a total serum IgE level ≥ 30 to ≤ 700 IU/ml (suitable weight for dosing)
- Patients with the diagnosis of not adequately controlled seasonal grass pollen (and/or rye pollen) and allergic asthma with concomitant seasonal allergic rhinoconjunctivitis within > 2 previous seasons
- patients with a positive RAST (>CAP2) result for grass pollen (and/or rye pollen) specific IgE at screening (Visit 1 (V1) or within the previous 12 months.
- Patients with FEV1 > 80% of the predicted normal value for the patient at screening [V1](demostrable at least 6 hours after last short acting B-2 agonist use or 12 hours after last long B-2 acting agonist use).
Exclusion Criteria:
- Females of childbearing potential: pregnancy, birth control,breast-feeding
Concurrent diseases/conditions and history of other diseases/conditions
- patients who have a positive history of significant clinical manifestations of allergy as a result of sensitization against tree pollen allergens, weed allergens and perennial allergens (e.g. Aspergillus spores, animal dander, house dust mite).
- patients with a history of food or drug related severe anaphylactoid or anaphylactic reaction(s).
Ingredient hypersensitivity
- patients with known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication, any immunotherapy, or drugs related to Omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin).
- patients with hypersensitivity to the trail's asthma rescue- or escalation-medication or related drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Depigold+Omalizumab
Xolair® (Omalizumab, double-blind core study period only), Depigoid® (grass/rye pollen 50/50)
|
Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
anti-IgE (Omalizumab) given during the 2006 core study
Other Names:
|
Experimental: Depigoid+Placebo
Depigoid® (grass/rye pollen 50/50) + Placebo
|
Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
Placebo given during the 2006 core study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily Symptom Load
Time Frame: Recorded daily during the 2007 and 2008 pollen season
|
The daily symptom load (low=0, high=unbounded) represents the daily combined asthma and rhinoconjunctivitis symptom severity scores plus the daily asthma rescue medication score based on patient diary entries.
A higher score indicates a worse patient asthma condition.
Symptoms (e.g. - difficulty breathing, cough, tightness of chest, sneezing, itchy nose, red eyes, etc.) were evaluated daily by the patient using a 4-point scale (0=no symptom, 1=mild, 2=moderate, 3=severe).
Point values were assigned by specific rescue medication usage.
The daily scores were averaged over pollen days by site.
|
Recorded daily during the 2007 and 2008 pollen season
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Asthma/Rhinoconjunctivitis Symptom Severity Score
Time Frame: Recorded daily during the 2007 and 2008 pollen season
|
The symptom severity score was defined as the mean of the daily symptom severity scores (asthma symptoms during the day, asthma symptoms at night, rhinitis symptoms, and conjunctivitis symptoms) during the pollen season.
The daily symptom severity scores were evaluated daily by the patient using a 4-point scale (0 = none (no symptom), 1 = mild, 2 = moderate, 3 = severe) and were recorded in a patient diary.
The possible minimum value for the Asthma/Rhinoconjunctivitis Symptom Severity Score is 0, and the possible maximum value is 3. Higher values represent a worse outcome.
|
Recorded daily during the 2007 and 2008 pollen season
|
Asthma/Rhinoconjunctivitis Rescue Medication Score
Time Frame: Recorded daily during the 2007 and 2008 pollen season
|
Asthma/Rhinoconjunctivitis rescue medication score is a component of symptom load.
Patients were advised that between visits they could take short acting β-2 agonist rescue medication as initial rescue medication for symptoms of intercurrent bronchospasm.
Patients were advised that between visits they could take rescue medication (systemic antihistamines) on an as-needed basis for symptoms of grass pollen allergic rhinoconjunctivitis.
The symptom load and all its components were based on the patient's entries in their diaries.
|
Recorded daily during the 2007 and 2008 pollen season
|
Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Investigator
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The investigator's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms.
GETE is scored as 1='excellent', 2='good', 3='moderate', 4='poor', 5='worsening' and (.)='missing').
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Percentage of Participants by Global Evaluation of Treatment Effectiveness (GETE) Assessment Category Performed by the Patient
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The patient's assessment of the global evaluation of treatment effectiveness (GETE) using a five point scale, which evaluates change in asthma control/symptoms.
GETE is scored as 1='excellent', 2='good', 3='moderate', 4='poor', 5='worsening' and (.)='missing').
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Asthma Control Questionnaire (ACQ)
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The Asthma Control Questionnaire (ACQ) was developed and validated for assessing asthma symptom control in patients in clinical trials as well as for individuals in clinical practice.
It is a simple questionnaire consisting of seven questions assessing symptoms, airway caliber and rescue β2-agonist use.
It uses a 7-point scale.
The possible minimum value is 1, the possible maximum value is 7. Higher values represent worse asthma control and quality of life, respectively.
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Asthma Quality of Life Questionnaire (AQLQ)
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The Asthma Quality of Life Questionnaire (AQLQ) is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma.
It consists of 4 domains (symptoms, emotions, exposure to environmental stimuli and activity limitation).
Patients are asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale.
The overall AQLQ score is the mean response to all 32 questions (low=1, high=7).
Higher values represent better quality of life.
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ)
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a 28-item disease specific questionnaire designed to measure functional impairments that are most important to patients with rhinoconjunctivitis.
It consists of 7 domains (activities, sleep, common complaints, practical problems, nasal symptoms, ocular symptoms, and emotions).
Patients recall their experiences during the previous week and to score each item on a 7-point scale.
The overall RQLQ score is the mean response to all 28 questions (low=1, high=7).
Higher values represent worse quality of life.
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Asthma Quality of Life Questionnaire (AQLQ) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Clinical Differences to Baseline
Time Frame: Baseline of core study and 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Both the AQLQ and RQLQ clinical differences were categorized as important, moderate, or meaningful improvement; no clinical change; meaningful, moderate, or important impairment.
Clinically important differences in scores between any two assessments have been determined by the authors of the AQLQ and RQLQ.
Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and > 1.5 as marked clinically important differences for any individual domain or for the overall summary score.
|
Baseline of core study and 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Work Productivity and Activity Impairment
Time Frame: 52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
The Work Productivity and Activity Impairment questionnaire measures time missed from work, impairment of work and regular activities.
It consists of 6 items.
The outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
The minimum value is 0 (0 %), the maximum value is 1 (100%).
The recall time is 1 week.
For this study WPAI-AA was used defining the specific health problem as allergic asthma, which has been validated by the instrument owner.
|
52 Weeks (2007) and 104 Weeks (2008) after completion of core study
|
Lung Function as Assessed by Forced Expiratory Volume in One Second (FEV1)
Time Frame: Assist during 2007 and 2008 pollen season
|
The spirometric parameter Forced Expiratory Volume in One Second (FEV1) was measured during grass pollen season before each injection of Depigoid.
|
Assist during 2007 and 2008 pollen season
|
Lung Function as Assessed by Peak Expiratory Flow (PEF)
Time Frame: Assist during 2007 and 2008 pollen season
|
The spirometric parameter Peak Expiratory Flow (PEF) was measured during grass pollen season before each injection of Depigoid.
PEF was collected in the patient diary at seven days after visit 22, 23 and 24 as well as 35, 36 and 37.
For analyzing purposes these data were averaged after the respective visits.
Missing PEF-values from the patient diary were not replaced.
|
Assist during 2007 and 2008 pollen season
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Novartis Pharmaceuticals, Novartis Pharmaceuticals, Basel +41 61 324 1111.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIGE025ADE03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Asthma
-
University of ZurichUniversity of AarhusActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Rhinitis, Allergic, Seasonal | Allergic Asthma | Rhinitis; Allergic, With AsthmaSwitzerland
-
Children's Mercy Hospital Kansas CityCompletedAsthma | Allergic Asthma | Non-allergic AsthmaUnited States
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
The Cleveland ClinicEnrolling by invitation
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LNot yet recruitingPerennial Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | House Dust Mite AllergySpain
-
University Hospital, AkershusOslo University Hospital; ImmunoPharma ASCompletedAllergic Asthma | Allergic Rhinoconjunctivitis | Immune ToleranceNorway
-
Johann Wolfgang Goethe University HospitalCompleted
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)TerminatedMild Allergic Rhinitis | Mild Allergic Rhinitis With Mild AsthmaUnited States
Clinical Trials on Depigoid
-
Plaza del Hospital CivilLaboratorios Leti, S.L.CompletedAllergic RhinitisSpain
-
Leti Pharma GmbHCompletedAllergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma | Sensitization Against Betula Alba (Birch) PollenGermany
-
Laboratorios Leti, S.L.Harrison Clinical ResearchTerminatedAllergic Rhinitis | Mild Persistent Asthma | Rhinoconjunctivitis | Mild Intermittent AsthmaSpain
-
Laboratorios Leti, S.L.CompletedAllergy | Rhinitis | Rhinoconjunctivitis | Seasonal AsthmaSpain
-
Laboratorios Leti, S.L.Terminated
-
Leti Pharma GmbHCompletedAllergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma | Sensitization Against Phleum Pratense Pollen | Dose-Finding StudyGermany
-
Leti Pharma GmbHPierrel Research Europe GmbH; Laboratorios LETI SL (Study Medication); Labor...CompletedAllergic Rhinitis and/or Rhinoconjunctivitis +- Asthma | Immunotherapy, AllergenGermany, Lithuania, Poland
-
Laboratorios Leti, S.L.CompletedAllergic RhinoconjunctivitisSpain